Update on second primary malignancies in multiple myeloma: a focused review. - Wikidata - wikimedia - TriplyDB

Update on second primary malignancies in multiple myeloma: a focused review.

Update on second primary malignancies in multiple myeloma: a focused review.

http://www.wikidata.org/entity/Q38178031

about

Learning about the Importance of Mutation Prevention from Curable Cancers and Benign Tumors New cancers after autotransplantations for multiple myeloma.Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma.Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries Therapy-related acute promyelocytic leukemia in plasma cell myeloma treated with melphalan: a case report and literature review Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.The risk of secondary primary malignancies after therapy for multiple myeloma.Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.Allogeneic bone marrow transplantation for therapy-related acute lymphocytic leukemia after autologous hematopoietic stem cell transplantation for multiple myeloma.

P2860

Q26766238-3CDEC633-E444-4195-891B-27C479FDAE76 Q35177465-1291D4C3-93EE-44F4-9C50-F82031796DB7 Q36438206-EE8DC8C7-418E-46DC-B223-FB89964418C0 Q36611288-F33732D0-56D5-40BE-BCB9-5ECBB1BDFC8F Q37740419-9C67E62D-382B-4665-BD3B-AF10831C3B2F Q38379791-AD8748AE-B615-4EA1-9127-0C378F206D50 Q38462594-C5EDB0DE-594E-44E2-8DDE-FF1EF13A528C Q38551337-2A788744-8246-449B-8CC9-D119BE398D45 Q38650700-3876AB42-6F87-42BA-A169-A12720D128CB Q39013620-6C3ECEC0-34EA-4E7D-837D-9E7F1DC3E928 Q40977353-32299518-1149-461D-A58E-C12E6C251800 Q50232489-3BEA7989-82CA-4AB8-B3E4-C4AB3D6C94AC

P2860

Update on second primary malignancies in multiple myeloma: a focused review.

http://www.wikidata.org/entity/Q38178031

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Update on second primary malignancies in multiple myeloma: a focused review.

@en

type

label

Update on second primary malignancies in multiple myeloma: a focused review.

@en

prefLabel

Update on second primary malignancies in multiple myeloma: a focused review.

@en

P1433

Q38178031-98A76934-5B13-4CCD-A20B-68FAD7EA7C82

P1476

Q38178031-27C4718E-AF9A-4FF3-BA33-436AADD1B691

P2093

Q38178031-85560D23-09EE-4A31-ACD0-27D2CA492F0A

Q38178031-CA0FAEAE-10B1-46ED-968A-492E49674229

P2860

Q38178031-2000AC2E-6780-4A8A-8F78-7A2C17F1CF41

Q38178031-2D03E172-112F-481F-A1E5-28BBB82BDCFF

Q38178031-316F7511-6AD6-4570-94B5-36D64139D225

Q38178031-44CE2761-C6FF-4286-ABDF-DCB891689EF6

Q38178031-47C2B226-C67F-48F3-B698-104ADE73AB69

Q38178031-496B05EF-A68B-4DF2-968F-C66859FC097D

Q38178031-667B0AFB-683A-4637-8320-19263E42368B

Q38178031-904421BC-6065-4B04-AF68-C18879D6D602

Q38178031-919FFDA4-A1D8-42FE-96B1-BA733F28EBEE

Q38178031-A3007143-4166-4EEF-87BF-CB7BAF42086C

P2888

Q38178031-C378D911-84BB-4552-A860-101B1E9797BC

P304

Q38178031-C176B55F-514D-4F21-A73A-67270774CF0A

P31

Q38178031-1FC16264-88EC-4017-8BF4-1BAF741D71DF

P356

Q38178031-869742C2-0DBE-4F88-96E6-EF240B21BD70

P433

Q38178031-CA8CC282-A83E-427C-BFD0-78822A512C20

P478

Q38178031-D4A2CD59-FA29-4864-B6A3-81E3C2B4AEB2

P577

Q38178031-C737A0DA-B8A8-4F6F-846A-A2C90A669B08

P6179

Q38178031-CFA6F271-1B9A-4B9B-BD87-5FFB07DB2082

P698

Q38178031-BBF76E79-666D-4889-9355-08C53E751397

P356

P1433

P1476

Update on second primary malignancies in multiple myeloma: a focused review.

@en

P2093

O Landgren

http://www.w3.org/2001/XMLSchema#string

S Mailankody

http://www.w3.org/2001/XMLSchema#string

P2860

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Chromosomal localization and cDNA cloning of the genes (DDB1 and DDB2) for the p127 and p48 subunits of a human damage-specific DNA binding protein

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

Lenalidomide after stem-cell transplantation for multiple myeloma

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

Second malignancies after multiple myeloma: from 1960s to 2010s.

P2888

P304

1423-1426

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2014.22

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1019841777

http://www.w3.org/2001/XMLSchema#string

P698

24418993

http://www.w3.org/2001/XMLSchema#string